Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

358.56 -1.20 (-0.33%)
Streaming Delayed Price Updated: 12:54 PM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years ↗
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.97% on an annualized basis producing an average annual return of 44.08%. Currently, Krystal Biotech has a market... 
Via Benzinga
Krystal Biotech (NASDAQ:KRYS) Clears Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
News headline image
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗
The drugmaker should significantly mitigate its most important risk as it develops new products. 
Via The Motley Fool
News headline image
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript ↗
VYJUVEK revenue surged 24% as the company eyes a multiproduct pipeline transition. 
Via The Motley Fool
Topics Earnings
Krystal Biotech (NASDAQ:KRYS) Slips After Q2 Revenue Miss Despite EPS Beat ↗
Via Chartmill
Krystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setup ↗
Via Chartmill
Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum ↗
Via Chartmill
News headline image
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today ↗
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.0% on an annualized basis producing an average annual return of 42.63%. Currently, Krystal Biotech has a market... 
Via Benzinga
News headline image
Krystal Biotech Q2 Earnings Call Highlights ↗
Krystal Biotech (NASDAQ:KRYS) reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded... 
Via MarketBeat
Topics Earnings
News headline image
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗
They are riding strong tailwinds that could lift them higher. 
Via The Motley Fool
Topics Economy
News headline image
Why Tutor Perini Stock Trounced the Market on Tuesday ↗
It's about to join a notable small-cap stock index. 
Via The Motley Fool
Topics Stocks
Krystal Biotech (NASDAQ:KRYS) Surges After Q1 Beat as VYJUVEK Revenue Hits $116.4M ↗
Via Chartmill
News headline image
3 Soaring Stocks That May Have More Upside Ahead ↗
The sky is the limit for these companies. 
Via The Motley Fool
News headline image
3 Biotech Firms With Major Potential Catalysts in the Coming Months ↗
The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms. 
Via MarketBeat
Topics Intellectual Property
News headline image
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead ↗
They haven't peaked yet. 
Via The Motley Fool
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Tech Fund Made a $5.8 Million Bet on an AI Chip Stock Up Nearly 200% Post-IPO ↗
Ambiq Micro designs ultra-low-power chips for wearables, IoT, and edge AI, targeting energy efficiency in connected devices. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering Regulatory Compliance
News headline image
This AI Semiconductor Stock Beat the S&P 500 by 9 Points. A Fund Just Exited Completely ↗
Ambarella delivers advanced semiconductor solutions for video, AI, and computer vision across automotive, security, and robotics markets. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance Stocks
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology. 
Via The Motley Fool
News headline image
Krystal (KRYS) Q1 2026 Earnings Transcript ↗
Krystal (KRYS) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Krystal (KRYS) Q1 2025 Earnings Transcript ↗
Krystal (KRYS) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Is Paymentus Stock a Buy After Palisades Investment Partners Increased Its Stake By $6 Million? ↗
Paymentus delivers cloud-based bill payment technology to major enterprises across regulated and service-intensive industries. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Amprius Technologies Stock a Buy After Palisades Investment Partners Initiated a Position Worth $4.8 Million? ↗
Amprius Technologies manufactures silicon nanowire lithium-ion batteries for aerospace, defense, and electric mobility markets. 
Via The Motley Fool
Topics Electric Vehicles Regulatory Compliance
News headline image
Palisades Investment Partners Initiated a Position in SkyWater Technology Stock. What Does This Mean for Investors? ↗
SkyWater Technology delivers custom semiconductor solutions for sectors including aerospace, automotive, and industrial IoT. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
These companies boast significant upside potential. 
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals' Empire in Trouble? ↗
It might not be too late to invest in this company. 
Via The Motley Fool
News headline image
Could This Under-the-Radar Healthcare Stock Set You Up for Life? ↗
The biotech is off to a pretty decent start. 
Via The Motley Fool
News headline image
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.